Segurança e eficácia do ramo da esquerda ramificações de ramo versus terapia convencional de ressincronização cardíaca na insuficiência cardíaca (SYNCHRONICITY)
This study will compare two different methods to pace the heart to treat heart failure including:
- The current standard method of implanting a pacing lead in a vein on the surface of the left lower chamber of the heart (left ventricle) to deliver heart failure therapy. This method is called Cardiac Resynchronization Therapy (CRT).
- The other method is using a lead implanted in the Left Bundle Branch Area (LBBA) of your heart. This method is called Left Bundle Branch Area Pacing or LBBAP. This lead is approved by the Food and Drug Administration (FDA) to be implanted in this area of the heart, but not to provide heart failure treatment.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Jacqueline Beaulieu
- Número de telefone: 1-800-227-3422
- E-mail: jacqueline.beaulieu@bsci.com
Locais de estudo
-
-
Alabama
-
Huntsville, Alabama, Estados Unidos, 35801
- Recrutamento
- Heart Center Research, LLC
-
Contato:
- John Jennings, Dr.
-
Investigador principal:
- John Jennings, Dr.
-
Mobile, Alabama, Estados Unidos, 36608
- Recrutamento
- Mobile Infirmary Medical Center
-
Contato:
- Ernest Matthew Quin, Dr.
-
Investigador principal:
- Ernest Matthew Quin, Dr.
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85054
- Recrutamento
- Mayo Clinic Phoenix
-
Contato:
- Mayank Sardana, MD
-
Investigador principal:
- Mayank Sardana, MD
-
-
Arkansas
-
Jonesboro, Arkansas, Estados Unidos, 72401
- Recrutamento
- Arrhythmia Research Group
-
Contato:
- Devi Nair, Dr.
-
Investigador principal:
- Devi Nair, Dr.
-
-
California
-
La Jolla, California, Estados Unidos, 92037
- Recrutamento
- Scripps Memorial Hospital
-
Contato:
- Nicolas Olson, MD
-
Investigador principal:
- Nicolas Olson, MD
-
Los Angeles, California, Estados Unidos, 90048
- Recrutamento
- Cedars Sinai Medical Center
-
Investigador principal:
- Ashkan Ehdaie, MD
-
Contato:
- Ashkan Ehdaie, MD
-
Oakland, California, Estados Unidos, 94609
- Recrutamento
- Alta Bates Summit Medical Center
-
Contato:
- Rajan Shah, Dr.
-
Investigador principal:
- Rajan Shah, Dr.
-
Santa Monica, California, Estados Unidos, 90404
- Recrutamento
- Pacific Heart Institute
-
Contato:
- Stephen Tang, MD
-
Investigador principal:
- Stephan Tang, MD
-
Torrance, California, Estados Unidos, 90505
- Recrutamento
- Torrance Medical Center
-
Investigador principal:
- Gene Kim, MD
-
Contato:
- Gene Kim, MD
-
Ventura, California, Estados Unidos, 93003
- Recrutamento
- Cardiology Associates Medical Group, Inc.
-
Contato:
- Jonathan Dukes, Dr.
-
Investigador principal:
- Jonathan Dukes, Dr.
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20010
- Recrutamento
- Washington Hospital Center
-
Contato:
- Cyrus Hadadi, MD
-
Investigador principal:
- Cyrus Hadadi, MD
-
-
Florida
-
Sarasota, Florida, Estados Unidos, 34239
- Recrutamento
- Sarasota Memorial Hospital
-
Contato:
- Antonio Moretta, Dr.
-
Investigador principal:
- Antonio Moretta, Dr.
-
Tampa, Florida, Estados Unidos, 33613
- Recrutamento
- AdventHealth Tampa
-
Investigador principal:
- Kenneth Yamamura, MD
-
Contato:
- Kenneth Yamamura, MD
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30309
- Recrutamento
- Piedmont Hospital
-
Contato:
- Kavita Krishnasamy, MD
-
Investigador principal:
- Kavita Krishnasamy, MD
-
Atlanta, Georgia, Estados Unidos, 30322
- Recrutamento
- Emory University Hospital
-
Contato:
- Anand Shah, MD
-
Investigador principal:
- Anand Shah, MD
-
-
Idaho
-
Meridian, Idaho, Estados Unidos, 83642
- Recrutamento
- St. Luke's Idaho Cardiology Associates
-
Contato:
- Justice Oranefo, MD
-
Investigador principal:
- Justice Oranefo, MD
-
-
Illinois
-
Hinsdale, Illinois, Estados Unidos, 60521
- Recrutamento
- University of Chicago
-
Contato:
- Shrinath Yeshwant, MD
-
Investigador principal:
- Shrinath Yeshwant, MD
-
Naperville, Illinois, Estados Unidos, 60540
- Retirado
- Midwest Cardiovascular Institute
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46250
- Recrutamento
- Community Heart and Vascular Hospital
-
Contato:
- Krishna Malineni, MD
-
Investigador principal:
- Krishna Malineni, MD
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- Recrutamento
- University of Iowa Hospitals and Clinics
-
Investigador principal:
- Paari Dominic, MD
-
Contato:
- Paari Dominic, MD
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40207
- Recrutamento
- Baptist Hospital East Louisville
-
Investigador principal:
- Kevin Parrott, MD
-
Contato:
- Kevin Parrott, MD
-
-
Massachusetts
-
Fall River, Massachusetts, Estados Unidos, 02720
- Recrutamento
- Southcoast Physicians Group
-
Contato:
- Arnoldas Giedrimas, MD
-
Investigador principal:
- Arnoldas Giedrimas, MD
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- Recrutamento
- University of Michigan Hospitals
-
Investigador principal:
- Thomas Crawford, MD
-
Contato:
- Thomas Crawford, MD
-
Grand Rapids, Michigan, Estados Unidos, 49525
- Recrutamento
- Corewell Health
-
Contato:
- Jawad Wassim, MD
-
Investigador principal:
- Jawad Wassim, MD
-
-
Minnesota
-
Duluth, Minnesota, Estados Unidos, 55805
- Retirado
- St. Mary's Duluth Clinic Regional Heart Center
-
Saint Cloud, Minnesota, Estados Unidos, 56303
- Retirado
- Centracare Heart and Vascular Center
-
-
New Jersey
-
Morristown, New Jersey, Estados Unidos, 07932
- Recrutamento
- Morristown Medical Center
-
Contato:
- Michael Katz, MD
-
Investigador principal:
- Michael Katz, MD
-
-
New York
-
Albany, New York, Estados Unidos, 12211
- Recrutamento
- Capital Cardiology Associates
-
Contato:
- Rizwan Alimohammad, MD
-
Investigador principal:
- Rizwan Alimohammad, MD
-
Flushing, New York, Estados Unidos, 11355
- Recrutamento
- New York Hospital Queens
-
Contato:
- Seth Goldbarg, Dr.
-
Investigador principal:
- Seth Goldbarg, Dr.
-
New York, New York, Estados Unidos, 10021
- Recrutamento
- Weill Cornell Medical University
-
Contato:
- Jim Cheung, Dr.
-
Investigador principal:
- Jim Cheung, Dr.
-
New York, New York, Estados Unidos, 14621
- Recrutamento
- Rochester General Hospital
-
Contato:
- Dmitry Chuprun, MD
-
Investigador principal:
- Dmitry Chuprun, MD
-
Syracuse, New York, Estados Unidos, 13057
- Recrutamento
- SUNY-Upstate Medical University
-
Contato:
- Jorge Romero, MD
-
Investigador principal:
- Jorge Romero, MD
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28204
- Recrutamento
- Sanger Heart and Vascular Institute
-
Contato:
- Navid Nafissi, MD
-
Investigador principal:
- Navid Nafissi, MD
-
Durham, North Carolina, Estados Unidos, 27710
- Recrutamento
- Duke University Medical Center
-
Contato:
- Daniel Friedman, MD
-
Investigador principal:
- Daniel Friedman, MD
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43219
- Recrutamento
- Mount Carmel Health System
-
Contato:
- Kamel Addo, MD
-
Investigador principal:
- Kamel Addo, MD
-
Columbus, Ohio, Estados Unidos, 43214
- Recrutamento
- OhioHealth Research and Innovation Institute-Riverside Methodist Hospital
-
Contato:
- Anish Amin, MD
-
Investigador principal:
- Anish Amin, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Recrutamento
- Penn Presbyterian Medical Center
-
Contato:
- John Bullinga, MD
-
Investigador principal:
- John Bullinga, MD
-
Wilkes-Barre, Pennsylvania, Estados Unidos, 18702
- Recrutamento
- Geisinger Wyoming Valley
-
Investigador principal:
- Pugazhendhi Vijayaraman, MD
-
Contato:
- Pugazhendhi Vijayaraman, MD
-
-
South Dakota
-
Sioux Falls, South Dakota, Estados Unidos, 57108
- Recrutamento
- Avera Heart Hospital of South Dakota
-
Contato:
- Christopher Stanton, Dr.
-
Investigador principal:
- Christopher Stanton, Dr.
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37205
- Recrutamento
- St.Thomas Health
-
Contato:
- Ricardo Lugo, MD
-
Investigador principal:
- Ricardo Lugo, MD
-
-
Texas
-
Plano, Texas, Estados Unidos, 75093
- Recrutamento
- Heart Hospital Baylor Plano
-
Contato:
- Mustafa Dohadwala, MD
-
Investigador principal:
- Mustafa Dohadwala, MD
-
Tyler, Texas, Estados Unidos, 75701
- Recrutamento
- Christus Trinity Mother Frances Health System
-
Contato:
- Stanislov Weiner, Dr.
-
Investigador principal:
- Stanislov Weiner, Dr.
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22908
- Recrutamento
- University of Virginia Medical Center
-
Investigador principal:
- Pamela Mason, MD
-
Contato:
- Pamela Mason, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Patient is age 18 years or above, or of legal age to give informed consent specific to state and national law
-
Patient meets a guideline-based indication for a de novo CRT-D device
-
Primary prevention indication for ICD therapy
-
Ischemic or nonischemic cardiomyopathy with LVEF ≤ 35% within 6 months of enrollment (LVEF must be assessed after the subject has been on GDMT for a minimum of 3 months) using an appropriate method of assessment (i.e. Echo, MRI, etc)
-
NYHA class II-IV despite maximally tolerated guideline directed medical therapy (GDMT)* for at least 3 months
*GDMT is defined as all four drug classes listed below for at least 3 months prior to enrollment unless the investigator provides justification (e.g., contraindicated, not tolerated or cost): Renin Angiotensin System Inhibitors (ACE, ARB, or ARNI) Evidence based betablockers (metoprolol succinate, carvedilol, bisoprolol) Mineralocorticoid antagonists SGLT2 Inhibitor medications
-
Sinus rhythm with left bundle branch block (LBBB) defined as a QRS ≥ 140 ms in men and ≥ 130 ms in women with a predominantly negative deflection (QS or rS in lead V1 and mid QRS notching or slurring in at least two of the following leads: 1, aVL, V1, V2, V5, V6) within 3 months of enrollment
-
Patient is willing to participate in LATITUDE™ NXT remote patient monitoring
-
Patient is willing and capable of providing informed consent and participating in all testing associated with this investigation at an approved study site and at the protocol defined intervals (Note: Use of a legally authorized representative (LAR) is not allowed)
-
Patient plans to remain geographically stable (not permanently moving to another location) and can commit to all study participation requirements (procedure, follow-up visits and testing requirements)
Exclusion Criteria:
- Persistent or permanent atrial fibrillation (AF) within 3 months prior to enrollment and documented in the medical record
- Frequent premature ventricular contractions (PVCs), atrial arrhythmias, and/or other causes of expected percentage of cardiac physiologic pacing (CPP) delivery below 95% at the time of enrollment
- Non-LBBB conduction abnormalities (including right bundle branch block (RBB) or intraventricular conduction delay (IVCD)) within 3 months prior to enrollment
- Complete, second degree or high degree atrioventricular (AV) block, that requires pacing at the time of enrollment
- Current or prior pacemaker, ICD or CRT implant (Also includes non-transvenous ICD technology and leadless pacemakers)
- Prior or planned mechanical or bioprosthetic tricuspid valve replacement
- Currently receiving or previously received positive inotrope therapy within 3 months prior to enrollment
- Unstable angina, acute myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention within 3 months prior to enrollment
- History of heart transplantation or left ventricular assist device (LVAD) implantation
- Less than 1 year of life expectancy at the time of enrollment
- Anticipated heart transplantation or LVAD implantation within 1 year of enrollment
- History of ventricular septal defect (VSD)
- Complex congenital heart disease
- Documented diagnosis of cardiac amyloidosis
- Known occlusion or other reason limiting central venous access for transvenous leads
- Women of childbearing potential who are, or plan to become, pregnant during the course of the study (assessment per investigator's discretion)
- Patient currently requiring dialysis
- Patient with known or suspected sensitivity to Dexamethasone Acetate (DXA)
- Patient with contrast dye allergy or unwilling/able to undergo pre-treatment with steroids and/or diphenhydramine
- Inability or refusal to comply with the follow-up schedule including subject living at such a distance from the investigational site that attending follow-up visits would be unusually difficult or burdensome
- Patient is enrolled in any other concurrent study. Co-enrollment into other studies such as observational studies/registries needs prior written approval by BSC. Local mandatory governmental registries are accepted for co-enrollment without approval by BSC.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: CRT Cohort
Participants will be randomized, implanted with a BSC CRT-D device using a Quadripolar lead, and device programmed to the respective cohort. |
Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), Quadripolar LV Lead. |
|
Experimental: LBBA Cohort
Participants will be randomized, implanted with a BSC CRT-D using the INGEVITY+ pace/sense lead implanted in the LBBA, and device programmed to the respective cohort. |
Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), INGEVITY+ pace/sense Lead (implanted in the LBBA) |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.
Prazo: Through study completion, up to maximum of 5 years
|
The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion. |
Through study completion, up to maximum of 5 years
|
|
System-related complication-free rate
Prazo: 12 months
|
The primary safety endpoint is System-related complication-free rate of LBBAP at 12 months. This will be a single-arm analysis of the LBBAP group compared to a performance goal |
12 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Win ratio composite assessment
Prazo: Through study completion, up to a maximum of 5 years
|
Win Ratio Ranking: 1) Death 2) Heart Transplant/LVAD 3) Number of Heart Failure (HF) events (includes in-patient, out-patient and HF re-admission 4) Number of VT/VF episodes requiring device therapy or external defibrillation/cardioversion (one episode per 24 hours 5) Change in MLHFQ (Minnesota Living with Heart Failure Questionnaire) quality of life |
Through study completion, up to a maximum of 5 years
|
|
Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.
Prazo: Through study completion, up to a maximum of 5 years
|
The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion. |
Through study completion, up to a maximum of 5 years
|
|
System-related complication-free rate between randomized arms
Prazo: 12 months
|
System-related complication-free rate of LBBAP at 12 months. This will compare the two randomized arms. |
12 months
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- C2403
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .